Sino Biopharmaceutical to acquire Hygieia for CNY1.2bn.

Sino Biopharmaceutical, a pharmaceutical conglomerate, agreed to acquire Hygieia, a clinical-stage biopharmaceutical company focused on developing innovative RNAi medicines, for CNY1.2bn. The $172m acquisition will bring in Kylo-11, a Lp(a) inhibitor with potential once-yearly dosing, as well as other ultra long-acting siRNA candidates directed at APOC3, PCSK9 and other undisclosed targets in cardiovascular diseases.